Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#3329 The role of 68Ga-DOTATATE PET/CT in extensive IgG4-positive fibrosis surrounding a mesenteric lymph node metastasis of a neuroendocrine tumor: A case report

Introduction: IgG4 expression is commonly seen in mesenteric tumor deposits from small intestine neuroendocrine tumors leading to a dense fibrotic response which can simulate IgG4-related sclerosing mesenteritis in medical images, hereby impeding a correct diagnosis.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author:

Authors: Ahmadi Bidakhvidi N, Cuyle P, Sagaert X, Ballaux F, De Bruecker Y,

Keywords: small intestine neuroendocrine tumor, 68Ga-DOTATATE PET/CT, mesenterial lymph node, fibrosis, IgG4,

#2071 ElevatION:NET-201 A Phase II Study to Evaluate the Efficacy and Safety of PDR001 in Patients with Metastatic, Well-Differentiated NET of Pancreatic/GI/Thoracic Origin or Poorly-Differentiated GEP NEC Who Have Progressed on Prior Treatment

Introduction: Monoclonal antibody (mAb) inhibitors of immune checkpoints, including anti–PD-1 and anti–PD-L1, have become established treatment options in various solid tumors. However, there is a paucity of data on treatment effect of checkpoint inhibition in neuroendocrine tumors (NET) and neuroendocrine carcinoma (NEC). PDR001 is a high-affinity, humanized IgG4 mAb directed against PD-1 that blocks the binding of PD-L1 and PD-L2 to PD-1.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Yao J, Fazio N, Li D, Pavel M, Strosberg J,

Keywords: PDR001, immunotherapy, NET,

#1847 CXCR4 Inhibition by Ulocuplumab Prevents EMT of pNET Cells in Vitro

Introduction: Neuroendocrine tumors (NETs) overexpress CXCR4. We have previously shown that stimulation of CXCR4 by its ligand SDF-1 promotes the epithelial-mesenchymal transition (EMT) and increases distant tumor spread. Ulocuplumab (Ulo) is a fully human IgG4 mAb designed to inhibit the binding of CXCR4 to SDF-1.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Quaresmini D

Authors: Quaresmini D, Cives M, Pellè E, Ungaro A, Felici C,

Keywords: pNET, CXCR4, EMT, Ulocuplumab,